Back to Agenda
Regulatory Science Hand in Hand with Health Technology Assessment for Better Outcomes
Session Chair(s)
Karin Van Baelen, PharmD
Head, Global Regulatory Affairs, Janssen, Belgium
This session will provide insights from key stakeholders on the impact of regulatory science, pharmaceutical legislation and HTA on the effectiveness of the EU regulatory system’s ability to overcome obstacles and focus on better outcomes for patients’ health.
Speaker(s)
Hugo Hurts
Chair HMA Brexit Task Force; Executive Director, Medicines Evaluation Board (MEB), Netherlands
Is Our Regulatory System Effective? Recent Examples of Applied Regulatory Science
Richard Bergström, MS
Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium
The Beauty of New Science - What Is Needed to Translate It into Better Outcomes? An Industry Perspective
Ioana-Raluca Siska, MD, PhD
Policy Officer, Health Technology Assessment, European Commission, Belgium
How Does the Regulatory and HTA System Keep Pace with New Science? EU Commission Perspectives on the EU Pharmaceutical Framework and HTA Cooperation
Have an account?